drugset / Trial / NCT06979505
GV101 in Healthy Obese Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2026-01-28
- Completion
- 2026-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GV101 | Unknown | — | — |
Indications
No indication recorded.